Equity Overview
Price & Market Data
Price: $1.28
Daily Change: +$0.024 / 1.88%
Range: $1.22 - $1.50
Market Cap: $3,435,609
Volume: 22,240
Performance Metrics
1 Week: 13.13%
1 Month: 4.92%
3 Months: -46.76%
6 Months: -36.00%
1 Year: -61.79%
YTD: -36.94%
Company Details
Employees: 2
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.